Education
About Us
Working with TipRanks
Follow Us
Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
CPH Stock Chart & Stats
C$14.69
C$0.11(0.75%)
At close: 4:00 PM EST
C$14.69
C$0.11(0.75%)
Day’s Range― - ―
52-Week RangeC$10.61 - C$17.50
Previous CloseN/A
Volume17.82K
Average Volume (3M)26.25K
Market Cap
C$372.68M
Enterprise ValueC$351.66M
Total Cash (Recent Filing)C$8.42M
Total Debt (Recent Filing)C$13.39M
Price to Earnings (P/E)15.6
Beta0.35
Next Earnings
Mar 12, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding25,369,642
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)2.40
Price to Sales (P/S)7.37
P/FCF Ratio12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$19.99Price Target Upside36.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$10.61 and its highest was C$17.50 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$372.68M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 81 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported C$0.29 earnings per share for the quarter, the consensus estimate of C$0.29 by C$0.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,369,642 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.29 in its last earnings report, expectations of C$0.29. Following the earnings report the stock price went down -9.011%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$19.99 (36.07% Upside)
C$19.99 (36.07% Upside)
Insider Transactions
Sold Shares
Worth $102.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
16.32%
Trailing 12-Months
Asset Growth
62.28%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. (CPH) is a Canadian specialty pharmaceutical company focused on developing and commercializing innovative prescription products, primarily in the dermatology and pain management sectors. The company is dedicated to enhancing patient care through the development of high-quality formulations and leveraging partnerships to bring effective treatments to market. Cipher's core products include a range of topical and oral medications designed to address various medical conditions, with a strategic emphasis on niche markets.
CPH Company Deck
CPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$19.99
▲(36.07% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---